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Systemic immune activation, a major determinant of human immunodeﬁciency virus (HIV) disease progres-
sion, is the result of a complex interplay between viral replication, dysregulation of the immune system, and
microbial translocation due to gut mucosal damage. Although human genetic variants inﬂuencing HIV load
have been identiﬁed, it is unknown how much the host genetic background contributes to interindividual dif-
ferences in other determinants of HIV pathogenesis such as gut damage and microbial translocation. Using
samples and data from 717 untreated participants in the Swiss HIV Cohort Study and a genome-wide associ-
ation study design, we searched for human genetic determinants of plasma levels of intestinal fatty acid–binding
protein (I-FABP/FABP2), a marker of gut damage, and of soluble CD14 (sCD14), a marker of lipopolysaccha-
ride bioactivity and microbial translocation. We also assessed the correlations between HIV load, sCD14, and
I-FABP. Although we found no genome-wide signiﬁcant determinant of the tested plasma markers, we observed
strong associations between sCD14 and both HIV load and I-FABP, shedding new light on the relationships
between processes that drive progression of untreated HIV infection.
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Human immunodeﬁciency virus (HIV) infection is
characterized by systemic immune activation, which
persists even with viral suppression by antiretroviral
therapy, and this immune activation is associated with
HIV pathogenesis and disease progression in treated and
untreated individuals [1, 2].One cause of immune activa-
tion is microbial translocation, which occurs when
microbial products from the lumen of the gastrointesti-
nal (GI) tract translocate into the systemic circulation
through a damaged GI tract barrier [3]. Immune acti-
vation and gut damage are cyclically linked, with immune
activation leading to damage of the structural and im-
mune barriers of the GI tract, and translocated microbial
products stimulating the systemic immune system. This
interplay is complex, and multiple factors affect each as-
pect of this vicious cycle, with the virus initiating and
driving the process in the absence of treatment.
Soluble CD14 (sCD14) is a biomarker found at the
heart of this interaction. Because it is a secreted sensor
of bacterial lipopolysaccharide (LPS), sCD14 acts as an
indirect marker of microbial translocation. The plasma
sCD14 levels were associated with mortality rates in 2
studies of HIV-infected individuals who were receiving
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antiretroviral therapy [4, 5]. Intestinal fatty acid–binding protein
(I-FABP encoded by FABP2) is a marker of GI tract enterocyte
damage [6] and thereby makes it possible to indirectly measure
structural damage to the GI tract, which would be prohibitive to
sample in a large cohort. The plasma levels of I-FABP also
showed some association with mortality rates in treated HIV-
infected populations and were inversely correlated with CD4+
T-cell counts [4, 5]. These plasma markers allow the large-scale
measurement of GI tract damage and microbial translocation.
Human genetic variation is known to play a modulating role in
the host response to HIV infection. Multiple genome-wide asso-
ciation studies (GWASs) have been performed in cohorts with
HIV control phenotypes, primarily in individuals of European
ancestry and mostly focusing on HIV load or disease progression
(CD4+ T-cell decline or time to AIDS) [7–10].These studies con-
sistently identiﬁed a small number of genetic variants associated
with viral control, including single-nucleotide polymorphisms
(SNPs) mapping to the HLA class I region on chromosome
6 and a 32–base pair deletion in the CCR5 gene (CCR5Δ32) on
chromosome 3. On the other hand, to our knowledge, there have
been no reported GWASs of GI tract damage or microbial trans-
location, so it is unknown towhat extent these essential aspects of
HIV pathogenesis are inﬂuenced by host genetic variation and
whether they also correlate with the HLA-B, HLA-C, and CCR5
variants associated with viral load.
Of note, early candidate gene studies reported the existence of
SNPs affecting sCD14 and I-FABP plasma levels, but these as-
sociations have yet to be conﬁrmed in HIV-infected populations
and in larger cohorts. The minor allele of rs2569190, a SNP
mapping to the CD14 promoter region, was associated with
higher plasma levels of sCD14 [11]. The same SNP was associ-
ated with signiﬁcant differences in secretion of sCD14 and in-
terleukin 6 in LPS-stimulated peripheral blood mononuclear
cells [12]. Two haplotypes have also been identiﬁed in the
FABP2 promoter (built from rs1799883, rs10034579, rs2282688,
and rs6857641) associated with I-FABP expression differences in
vitro [13, 14].
To elucidate how genetic factors may affect the interrelated
processes of viral replication, gut damage, and microbial trans-
location leading to systemic immune activation, we measured
the plasma levels of sCD14 and I-FABP in 717 untreated, clin-
ically and genetically well-characterized HIV-infected subjects
from the Swiss HIV Cohort Study (SHCS), and we used a
GWAS design to search for human genetic variants associated
with these biomarkers. We did not identify any signiﬁcant ge-
netic associations with sCD14 or I-FABP plasma levels, and we
found that the human genetic variants known to be associated
with HIV viremia are not associated with sCD14 or I-FABP lev-
els. On the other hand, we observed independent associations
between sCD14 and both HIV load and I-FABP, demonstrating
the intricate relationships that exist between the various patho-
genic mechanisms involved in HIV disease progression.
METHODS
Study Participants
The study subjects are part of the SHCS, a nationwide cohort
study with continuous enrollment and semiannual study visits
(www.shcs.ch [15]). The SHCS has been approved by the ethics
committees of all participating institutions. Each study partici-
pant provided written informed consent for genetic testing.
HIV-infected individuals were eligible if they had (1) genome-
wide genotyping data generated in the context of a previous
GWAS; (2) a stored plasma sample collected 3–6 years after esti-
mated date of seroconversion, in the absence of antiretroviral
treatment, and with a CD4+ T-cell count of ≥350/µL of blood;
and (3) ≥3 stable plasma HIV RNA results, obtained in the
absence of antiretroviral treatment, ≥6 months after the known
or presumed date of infection, and with a CD4+ T-cell count
of ≥350/µL of blood. The set point viral load was calculated as
the mean of all log10-transformed viral results ﬁtting these
conditions.
Plasma Biomarker Measurements
The I-FABP and sCD14 plasma levels were measured as de-
scribed elsewhere using commercially available enzyme-linked
immunosorbent assays [5]. The I-FABP assay (Cell Sciences)
was performed on plasma diluted to 50%, and the sCD14
assay (R&D Systems) on plasma diluted to 0.5%. All analyses
were performed with blinding to clinical and genetic status.
Each test was determined in duplicate, and the mean value of
each marker was calculated and used in the downstream
analyses.
Genotyping and Imputation
Genotyping was performed using the Illumina HumanHap550
array, as described elsewhere [8]. After quality control of the
genotyping data and exclusion of population outliers by princi-
pal component analysis [16], 686 individuals with complete
phenotype and genotype data were available for downstream
analysis. Genotypes were imputed using the 1000 Genomes Pro-
ject CEU reference panel: we used Mach1 software (v. 1.0.17) for
prephasing [17] and MiniMAC software for imputation [18].
Imputed SNPs with a minor allele frequency of ≥1% and an im-
putation quality score (r2) of ≥0.3 were kept for association test-
ing. The CCR5Δ32 variant, which is not represented directly or
indirectly on the genome-wide chip, was independently geno-
typed with a TaqMan assay.
Association Testing
We use GWAPower software (v. 1.0) for power calculation [19].
Association tests were carried out by linear regression using
PLINK software (v. 1.07) [20], and by linear mixed model
regression using FaST-LMM software (v. 2.0) [21]. The FaST-
LMM kernel matrix was computed from 69 000 randomly selected
SNPs (corresponding to 1% of the total number of tested SNPs).
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Regressions were performed against log10-normalized HIV load
at set point, log10-normalized sCD14 plasma levels, and log10-
normalized I-FABP plasma levels. Age, sex, and the coordinates
of the top 3 principal component analysis axes were included as
covariates in all regression models. We used Bonferroni correc-
tion for multiple testing. Statistics for the associations between
sCD14, I-FABP, viral load at set point, and the SNPs were com-
puted by means of linear regression using R software (v. 3.0).
RESULTS
Lack of Association Between Common Human Genetic Variants
and Markers of GI Tract Damage or Microbial Translocation
We analyzed HIV-infected patients that had been genotyped in
the context of a previous GWAS [8]. A total of 6 982 014 SNPs,
directly genotyped on Illumina arrays or imputed using the
1000 Genomes Project CEU population as reference, were avail-
able for association testing. Stored plasma samples were
obtained from eligible treatment-naive subjects, and the plasma
levels of I-FABP and sCD14 were measured using enzyme-
linked immunosorbent assay. A total of 717 participants had
complete genetic and phenotypic data, of whom 31 were iden-
tiﬁed as population outliers by principal component analysis of
the genotyping data and excluded. Therefore, the ﬁnal study
population included 686 individuals of European ancestry.
Demographic and laboratory information for all study partici-
pants is shown in Table 1.
No associations were found between any human SNP and
the plasma levels of I-FABP or sCD14 during early chronic,
untreated HIV infection, after correction for multiple testing
(Figure 1). Our study was powered to detect genetic variants
that explain ≥4% of the variability in sCD14 or I-FABP plasma
levels.
We also speciﬁcally looked at the SNPs that were reported
elsewhere to be associated with sCD14 and I-FABP plasma lev-
els. We did not observe any association between sCD14 plasma
levels and the CD14 promoter SNP rs2569190 (P = .46) or be-
tween I-FABP plasma levels and the FABP2 promoter SNPs
rs1799883, rs10034579, rs2282688, and rs6857641, alone or in
haplotype combinations (all P > .30).
Association of I-FABP Plasma Levels and HIV Load With sCD14
Plasma Levels
We next examined the correlations between several factors
known to play a role in HIV pathogenesis: HIV load at set
point, CD4+ T-cell count, plasma sCD14 level, and plasma
I-FABP level. CD4+ T-cell counts were not associated with
sCD14 or I-FABP plasma levels (P > .50 and r2 < 0.01 for both),
and this parameter was excluded from subsequent analyses. Of
note, the distribution of CD4+ T-cell counts was truncated
owing to the inclusion criterion that all study participants have
CD4+ T-cell counts >350/µL; the median cell count was 452/µL
in the study population (interquartile range, 390–566/µL).
We observed a moderate correlation between plasma levels
of I-FABP and sCD14 (P = 7.1 × 10−16; r2 = 0.09; Figure 2A),
conﬁrming the obvious link between GI tract damage and mi-
crobial translocation. This correlation was largely independent
of HIV load (P = 3.5 × 10−15 when viral load was included as a
covariate in the regression model).
The HIV plasma load at set point was strongly associated with
sCD14 but not with I-FABP plasma levels (P = 7.1 × 10−8 and
P = .20, respectively; Figure 2B and 2C). The strong association
observed between viral load and sCD14 plasma levels during
chronic untreated infection is consistent with a cyclical relation-
ship between HIV replication and immune activation due to
microbial translocation. On the other hand, the absence of cor-
relation between viral load and I-FABP concentration suggests
that the virus is not a major driver of GI tract damage during
the chronic phase of infection. This ﬁnding is consistent with
the fact that this marker of enterocyte damage can still be detect-
ed in individuals receiving suppressive antiretroviral therapy [2].
Human Genetic Variants Associated With HIV Control but Not
With sCD14 or I-FABP Plasma Levels
Three genetic variants have been consistently shown to be
associates with HIV control in previous GWAS: rs2395029, a
near-perfect proxy for HLA-B*57:01 in Europeans; rs9264942,
an indirect marker of HLA-C expression levels; and the
CCR5Δ32 deletion in its heterozygous form. We tested them
for association with viral load at set point in linear regression
models that included sex, age, and the coordinate of the top 3
principal component axes as covariates. The associations were
again signiﬁcant for all 3 variants in our study population
(Table 2). However, there was no association with sCD14 or
I-FABP plasma levels (all P > .05).
To further explore the potential interactions between HIV
load at set point, host genetic variants and sCD14 plasma levels,
we performed multivariate regression analyses on viral loads,
Table 1. Demographic and Laboratory Characteristics
Characteristic
Eligible
Participants
(n = 717)
Final Study
Population
(n = 686)
Male sex, No. (%) 543 (75.7) 520 (75.8)
Age, median (IQR), y 33 (27–40) 34 (28–40)
HIV load at set point, mean (SD),
log10 copies/mL
3.81 (0.96) 3.81 (0.96)
CD4+ T-cell count,
median (IQR), cells/µL
460 (390–571) 452 (390–556)
sCD14, mean (SD), log10 pg/mL 6.23 (0.13) 6.24 (0.13)
I-FABP, mean (SD), log10 pg/mL 2.70 (0.61) 2.70 (0.60)
Abbreviations: HIV, human immunodeficiency virus; I-FABP, intestinal fatty
acid–binding protein; IQR, interquartile range; sCD14, soluble CD14; SD,
standard deviation.
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Figure 1. No single-nucleotide polymorphisms are signiﬁcantly associated with intestinal fatty acid–binding protein (I-FABP) or soluble CD14 (sCD14)
plasma levels. Manhattan plots show the distribution of results for the 2 genome-wide association studies, for I-FABP (A) and sCD14 (B) plasma levels.
Horizontal axes represent human chromosomes in linear order; vertical axes, association strengths as −log10 P values.
Figure 2. Intestinal fatty acid–binding protein (I-FABP) and human immunodeﬁciency virus (HIV) load at set point are independently associated with
soluble CD14 (sCD14). Correlations are shown between plasma levels of I-FABP and sCD14 (P = 7.1 × 10−16; r 2 = 0.09) (A), sCD14 and HIV load
(P = 7.1 × 10−8; r 2 = 0.04) (B ), and I-FABP and HIV load (P = .2; r 2 < 0.01) (C ).
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including the 3 genetic variants as independent variables, with
or without sCD14 plasma levels in the model: rs2395029,
rs9264942, and CCR5Δ32 remained signiﬁcant predictors of
viral load, and the strength of the association did not change
signiﬁcantly when the regressions included sCD14 plasma lev-
els (Table 2). Thus, the previously described genetic variants in
the HLA-B, HLA-C, and CCR5 regions and the sCD14 plasma
levels are independently associated with HIV load at the set
point.
DISCUSSION
HIV pathogenesis is the result of a complex interaction between
the virus and the host response, which results in immune dys-
regulation. Many factors have been identiﬁed that independent-
ly contribute to pathogenesis, but their intricate relationships
have yet to be fully elucidated. In particular, host genetic factors
and systemic immune activation due to the translocation of
microbial products from the gut have both been shown to
have a strong impact on HIV control and disease progression,
but these have not been studied in relation to each other. We
therefore sought to measure plasma markers of GI tract damage
and microbial translocation in clinically and genetically well-
characterized patients from the SHCS.
We performed a GWAS searching for human genetic determi-
nants of sCD14 or I-FABP plasma levels, and we failed to identify
signiﬁcantly associated variants after correction for multiple test-
ing. Because our study was powered to detect variants that
explain ≥4% of sCD14 or I-FABP variability, we conclude that
the plasma levels of these biomarkers are not primarily deter-
mined by common genetic variants with moderate to high
effects.
We did not observe any association between a previously re-
ported CD14 promoter variant and sCD14 plasma levels, which
strongly suggests that in untreated HIV-infected individuals,
this biomarker primarily reﬂects LPS bioactivity or microbial
translocation rather than underlying genotype, in keeping
with the demonstrated strength of this measurement as a pre-
dictive biomarker of disease progression. Of note, in the original
report [11], homozygosity for the rs2569190 minor allele
was associated with only a 0.04 log10-transformed sCD14
increase, whereas the range of log10-transformed sCD14 values
was 5.9–6.6 (Δ = 0.7) in our study population. Similarly, we did
not identify any association between FABP2 genotypic variation
[13, 14] and plasma levels of I-FABP, which suggests that enter-
ocyte damage, rather than genetically determined expression
differences in I-FABP, drives the plasma level of I-FABP in
HIV-infected patients.
We then searched for associations between sCD14 and
I-FABP plasma levels and the degree of spontaneous HIV con-
trol (as reﬂected in viral load) during the chronic phase of HIV
infection, and we found that sCD14 strongly associates with
both I-FABP and viral load. Much of the previous work on
sCD14 and I-FABP has focused on treated HIV infection, be-
cause gut damage, microbial translocation and systemic inﬂam-
mation are the focus of current therapeutic efforts to decrease
the non-AIDS morbid effects and premature death observed
in patients with suppressed viremia receiving antiretroviral
therapy. In a cohort of mostly treated HIV-infected individuals,
Sandler et al [5] found a large increase in the risk of death with
higher plasma sCD14 levels and an inverse association between
plasma I-FABP level and CD4+ T-cell counts. A recent study by
Hunt et al [4] found a signiﬁcant correlation between I-FABP
and sCD14 levels in treated subjects with advanced disease,
and each marker strongly predicted mortality independently
of CD4+ T-cell count [4]. In fact, a similar correlation between
gut damage and LPS-induced monocyte activation has also
been observed in HIV-negative subjects [22].
To date, only a single study has examined the predictive value
of sCD14 for mortality in untreated chronic HIV infection [23]:
sCD14 levels were correlated with both viral load and CD4+
T-cell count, and the association of sCD14 with disease progres-
sion was not independent of these parameters. Our study adds
to this important area of research by also including a marker of
enterocyte damage and testing the relationships between all
these parameters in a larger, genetically homogeneous group
of untreated individuals.
Our observation that I-FABP is associated with sCD14 but
not with viral load during chronic untreated infection suggests
that, although the virus itself begins and reinforces the vicious
cycle of enterocyte damage, translocation of microbial products,
and immune activation, these processes may become largely in-
dependent of viral replication in the chronic phase of untreated
infection. This would be consistent with the high levels of im-
mune activation that can still be observed in some individuals
during fully suppressive antiretroviral therapy [2]. The interac-
tion between these measures is likely to be bidirectional, because
Table 2. P Values for Association With HIV Load at Set Point in
Linear Regression Models Including Sex, Age, and Coordinates of
the Top 3 Principal Components Axes as Covariates
Variant
P Value
Univariate
Models
Multivariate Models
Genetic
Variants Only
Genetic Variants
Plus sCD14
rs2395029 5.4 × 10−8 9.6 × 10−6 6.7 × 10−6
rs9264942 1.3 × 10−10 3.3 × 10−7 5.40 × 10−7
CCR5Δ32 .02 .02 .02
sCD14 levels 7.1 × 10−8 . . . 1.90 × 10−7
Abbreviations: HIV, human immunodeficiency virus; sCD14, soluble CD14.
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enterocyte damage allows microbial translocation and sCD14
increase due to LPS-induced monocyte activation, whereas
chronic immune activation is likely to further damage the GI
tract barrier. Interestingly, this correlation between I-FABP
and sCD14 plasma levels was not observed in primary HIV in-
fection, suggesting that microbial translocation is not the pri-
mary driver of monocyte activation during the acute phase of
infection [24].
The strong association that we found between sCD14 and
viral load, which had already been described in a small group
of untreated patients [5], is most likely indirect. The presence
in plasma of microbial products, including LPS, leads not
only to higher sCD14 levels but also to systemic inﬂammation,
which is known to increase HIV load [25].
Considering the negative results of our genetic scan, speciﬁc
limitations of the study design need to be highlighted. Some
variability in sCD14 and I-FABP measurements was inevitable,
which probably had a negative impact on study power. Each
sample was tested in duplicate to deal with potential assay var-
iability, but owing to the lack of suitable samples we did not re-
peat the measurements at different time points, which would
have allowed a precise estimation of biological variability. An-
other potential confounder is the variable duration of HIV in-
fection (3–6 years) before sampling, potentially leading to
interindividual differences in disease progression. The exclusion
of patients with moderate to severe immunosuppression (CD4+
T cell count, <350/µL of blood) aimed at mitigating this issue.
The absence of genetic associations with plasma I-FABP or
sCD14 allows better interpretation of microbial translocation
data and demonstrates that the previously identiﬁed genetic
variants associated with HIV load are independent of sCD14.
Our ﬁnding of associations between sCD14 and both I-FABP
and viral load reinforces the centrality of microbial transloca-
tion in the pathogenesis of untreated HIV infection.
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